Please ensure Javascript is enabled for purposes of website accessibility

Invitae Surges on $1.4B Acquisition of ArcherDX

By Maxx Chatsko – Jun 22, 2020 at 12:33PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The genetic testing company pulled the trigger on its largest acquisition yet.

What happened

Shares of Invitae (NVTA -4.69%) rose as much as 48.4% today after the company announced the acquisition of ArcherDX. At a total transaction cost of $1.4 billion, it's easily the largest acquisition in the company's history. 

The combination will immediately boost Invitae's product offerings and growth prospects. Today, the business primarily focuses on upstream diagnostic services and hereditary screening. With the addition of ArcherDX, the technology platform will be augmented with new capabilities in cancer care monitoring and liquid and tissue biopsy analysis. 

As of 12:24 p.m. EDT, the growth stock had settled to a 44% gain.

A businessman tossing cash into the air.

Image source: Getty Images.

So what

There's a lot to unpack from the acquisition of ArcherDX. Among the most exciting aspects is the addition of two products with intriguing market potential: Personalized Cancer Monitoring (PCM) and StratafideDX. Each has received Breakthrough Device designation from the U.S. Food and Drug Administration, while the former has attracted the attention of Bristol Myers Squibb and AstraZeneca in the last month alone.

Investors should pay close attention to the cost of the acquisition. Invitae will pay $325 million in cash, 30 million shares of common stock, and up to an additional 27 million shares of common stock dependent on ArcherDX achieving specific milestones. The total transaction cost is up to $1.4 billion.

Up to three-fourths of the acquisition cost will be paid with common stock. Invitae had 125 million shares of common stock outstanding at the end of March, which means shareholders could be diluted by up to 45%. That's a steep price, but one investors are betting will be well worth it in the long run.

Now what

Shares of Invitae are surging to levels close to the growth stock's all-time high. Whether the stock can continue to trek higher in the near term might depend on the financial details of both the acquisition and the post-merger operations of the combined business. ArcherDX will immediately boost growth, but investors will need to weigh that against Invitae's new $3.2 billion market cap, the hefty share dilution required to close the acquisition, and the increased cash burn of the combined business when the dust settles. 

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bristol Myers Squibb and Invitae. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Invitae Stock Quote
Invitae
NVTA
$2.44 (-4.69%) $0.12
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$54.58 (-3.07%) $-1.73
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$70.71 (-0.81%) $0.58

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.